retatrutide phase 2 trial obesity nejm 2023 Triple–Hormone-Receptor Agonist for — A | Incretin triple agonist retatrutide (LY3437943)

An updated systematic review and network meta-analysis of GLP-1 receptor agonists and polyagonists ranked retatrutide at or near the top for weight loss among the modern agents, while also flagging that the strongest-effect agents tend to carry the highest adverse-event burden

Understanding GLP-1 Medications and their Benefits GLP-1 receptor agonists are commonly used to treat type 2 diabetes and obesity

The placebo group showed a 3 percent hypersensitivity rate, suggesting that some increase does occur with active medication, though the absolute numbers remain modest

The relationship between weight and sleep is complicated - poor sleep quality definitely impacts weight loss and gain, and there is a need for trials in this space to better assess the potential impact

When you take these medications, you're essentially amplifying signals your body already uses to regulate appetite and satiety

Many patients avoid topiramate entirely once optimized on the right GLP-1 medication for their genetics